Breast Cancer Action Applauds FDA Recommendation to Deny Avastin for Breast Cancer Treatment

December 05, 2007

Breast Cancer Action Applauds FDA Recommendation to Deny Avastin for Breast Cancer Treatment
For Immediate Release Contact: Mary DeLucco Breast Cancer Action 415.243.9301 xt 16 Katrina Kahl Breast Cancer Action 415.243.9301 xt 19 San Francisco, CA—Breast Cancer Action (BCA) today applauded the recommendation by a Food & Drug Administration [...] READ MORE

December 03, 2007

Breast Cancer Action Calls for the FDA to Deny Avastin as a Breast Cancer Treatment
For Immediate Release Contact: Mary DeLucco Breast Cancer Action 415.243.9301 xt 16 Katrina Kahl Breast Cancer Action 415.243.9301 xt 19 San Francisco, CA—Breast Cancer Action (BCA) today called on the Food & Drug Administration to deny biotech co [...] READ MORE

November 08, 2007

Breast Cancer Action Applauds Anemia Drugs Warning; Questions Pharma Influence on FDA
For Immediate Release Contact: Mary DeLucco Breast Cancer Action 415.243.9301 xt 16 San Francisco, CA—Breast Cancer Action said that today’s action by the U.S. Food & Drug Administration warning about the risks that certain anemia drugs pose to [...] READ MORE

October 11, 2007

Breast Cancer Action Applauds New Direction in Breast Cancer Treatment Options
For Immediate Release Contact: Mary DeLucco Breast Cancer Action 415.243.9301 xt 16 Katrina Kahl Breast Cancer Action 415.243.9301 xt 19 San Francisco—Breast Cancer Action (BCA) said today that a new study that suggests that the chemotherapy drug T [...] READ MORE

October 01, 2007

Breast Cancer Action Launches 6th Year of Think Before You Pink
For Immediate Release Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 Katrina Kahl Breast Cancer (415) 243-9301 ext. 19 San Francisco—Breast Cancer Action (BCA) today launched its annual Think Before You Pink campaign with a new f [...] READ MORE

July 24, 2007

Breast Cancer Action Opposes Raloxifene Recommendation
For Immediate Release Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 San Francisco—Breast Cancer Action (BCA) opposes today’s recommendation by a U.S. Food and Drug Administration (FDA) advisory panel to approve the use of raloxifene ( [...] READ MORE

July 17, 2007

Breast Cancer Action Says New Study Proves Diet Does Not Play a Major Role in Breast Cancer
For Immediate Release Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 San Francisco, CA—Breast Cancer Action (BCA) said today it is not surprised that a new National Cancer Institute study finds that a diet high in vegetables, f [...] READ MORE

June 26, 2007

Breast Cancer Action Says Two New Drug Pricing Studies Miss the Mark
For Immediate Release: Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 San Francisco, CA—Breast Cancer Action (BCA) today expressed grave concerns about two new studies that purport to justify the exorbitantly high price of breast ca [...] READ MORE

June 19, 2007

Breast Cancer Action Cheers National Cancer Institute’s Decision to Cancel STELLAR “Prevention” Trial
For Immediate Release Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 San Francisco, CA—Breast Cancer Action (BCA) (www. bcaction.org) announced today its support for the National Cancer Institute’s decision not to go ahead with the P-4 [...] READ MORE

June 11, 2007

Breast Cancer Action Demands FDA Reform
For Immediate Release Contact: Mary DeLucco Breast Cancer Action (415) 243-9301 ext. 16 Breast Cancer Action Demands FDA Reform San Francisco, CA—Breast Cancer Action (BCA), a national grassroots education and advocacy organization, announced today t [...] READ MORE

May 21, 2007

FDA Approves MammaPrint Test
On February 6, 2007, the Food and Drug Administration (FDA) approved the MammaPrint test, a genetic test that aims to predict whether a woman diagnosed with breast cancer will have a recurrence of the disease within 5 to 10 years of the initial diagnosis [...] READ MORE